ADTX (Aditxt) Accounts Payable: $7.73 Mil (As of Mar. 2026)


What is Aditxt Accounts Payable?

Aditxt ADTX +1.28% Accounts Payable is $7.73 Mil as of Mar. 2026. The stock has 4 warning signs investors should review.

Aditxt's Accounts Payable for the quarter that ended in Mar. 2026 was $7.73 Mil.

Aditxt's quarterly Accounts Payable declined from Sep. 2025 ($10.36 Mil) to Dec. 2025 ($7.34 Mil) but then increased from Dec. 2025 ($7.34 Mil) to Mar. 2026 ($7.73 Mil).

Aditxt's annual Accounts Payable increased from Dec. 2023 ($7.52 Mil) to Dec. 2024 ($10.19 Mil) but then declined from Dec. 2024 ($10.19 Mil) to Dec. 2025 ($7.34 Mil).

Aditxt Accounts Payable Historical Data

* Premium members only.

The historical data trend for Aditxt's Accounts Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Aditxt Accounts Payable Chart

Aditxt Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Accounts Payable
Get a 7-Day Free Trial Premium Member Only 0.00 0.00 7.52 10.19 7.34

Aditxt Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Accounts Payable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 6.65 9.68 10.36 7.34 7.73

Aditxt Accounts Payable Calculation

Accounts Payable represents any money that a company owes its suppliers for goods and services purchased on credit and is expected to pay within the next year or operating cycle.

Frequently Asked Questions Learn more about Accounts Payable →
What does a Accounts Payable of $7.73 Mil mean?
Aditxt (ADTX) has a Accounts Payable of $7.73 Mil as of Mar. 2026. Accounts Payable is any money that a company owes for goods and services purchased on credit and is expected to pay within the next year. View historical data on Aditxt and its competitors.
Is Aditxt's Accounts Payable too high?
Aditxt's current Accounts Payable is $7.73 Mil.
How does Aditxt's Accounts Payable compare to AAGH and PKTX?
Aditxt's Accounts Payable of $7.73 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Accounts Payable for a Biotechnology company?
A good Accounts Payable depends on the Biotechnology industry context. However, Accounts Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Accounts Payable mean?
A high Accounts Payable can signal that a stock is expensive relative to its fundamentals. Accounts Payable is any money that a company owes for goods and services purchased on credit and is expected to pay within the next year. View historical data on Aditxt and its competitors. Aditxt's current Accounts Payable is $7.73 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aditxt stock overvalued right now?
Aditxt (ADTX) has a current Accounts Payable of $7.73 Mil. The current Accounts Payable is $7.73 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Accounts Payable calculated?
Accounts Payable is calculated from a company's financial statements. For Aditxt (ADTX), the current Accounts Payable is $7.73 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Aditxt Business Description

Address 2569 Wyandotte Street, Suite 101, Mountain View, CA, USA, 94043
Aditxt Inc is a life sciences company that develops, builds, and grows innovations with a focus on monitoring and modulating the immune system. It develops products designed to induce tolerance to transplanted organs. Its portfolio consists of two programs Adimune and AditxtScore. It firm's immunosuppressive (anti-rejection) drugs have made possible life-saving organ transplantation procedures and blocking of unwanted immune responses in autoimmune diseases. It is also developing a technology called Apoptotic DNA Immunotherapy (ADi) ADI-100, which utilizes a novel approach that mimics, the way bodies naturally induce tolerance to tissues. The company operates in one segment, which is focused on the discovery and development of biopharmaceutical products.